Recent Advances in the Elucidation of Frataxin Biochemical Function Open Novel Perspectives for the Treatment of Friedreich's Ataxia

Overview

Journal Front Neurosci

Date 2022 Mar 21

PMID 35310092

Authors

Beata Monfort

Kristian Want

Sylvain Gervason

Benoit DAutreaux

Affiliations

Soon will be listed here.

Abstract

Friedreich's ataxia (FRDA) is the most prevalent autosomic recessive ataxia and is associated with a severe cardiac hypertrophy and less frequently diabetes. It is caused by mutations in the gene encoding frataxin (FXN), a small mitochondrial protein. The primary consequence is a defective expression of FXN, with basal protein levels decreased by 70-98%, which foremost affects the cerebellum, dorsal root ganglia, heart and liver. FXN is a mitochondrial protein involved in iron metabolism but its exact function has remained elusive and highly debated since its discovery. At the cellular level, FRDA is characterized by a general deficit in the biosynthesis of iron-sulfur (Fe-S) clusters and heme, iron accumulation and deposition in mitochondria, and sensitivity to oxidative stress. Based on these phenotypes and the proposed ability of FXN to bind iron, a role as an iron storage protein providing iron for Fe-S cluster and heme biosynthesis was initially proposed. However, this model was challenged by several other studies and it is now widely accepted that FXN functions primarily in Fe-S cluster biosynthesis, with iron accumulation, heme deficiency and oxidative stress sensitivity appearing later on as secondary defects. Nonetheless, the biochemical function of FXN in Fe-S cluster biosynthesis is still debated. Several roles have been proposed for FXN: iron chaperone, gate-keeper of detrimental Fe-S cluster biosynthesis, sulfide production stimulator and sulfur transfer accelerator. A picture is now emerging which points toward a unique function of FXN as an accelerator of a key step of sulfur transfer between two components of the Fe-S cluster biosynthetic complex. These findings should foster the development of new strategies for the treatment of FRDA. We will review here the latest discoveries on the biochemical function of frataxin and the implication for a potential therapeutic treatment of FRDA.

Citing Articles

Functional Characterization of Parallel Fiber-Purkinje Cell Synapses in Two Friedreich's Ataxia Mouse Models.

Joseph D, Mercado-Ayon E, Flatley L, Viaene A, Hordeaux J, Marsh E Cerebellum. 2025; 24(2):42.

PMID: 39907933 PMC: 11799031. DOI: 10.1007/s12311-025-01796-0.

Design and validation of cell-based potency assays for frataxin supplementation treatments.

Mukherjee S, Pereboeva L, Fil D, Saikia A, Lee J, Li J Mol Ther Methods Clin Dev. 2025; 32(4):101347.

PMID: 39823061 PMC: 11735916. DOI: 10.1016/j.omtm.2024.101347.

Harshly Oxidized Activated Charcoal Enhances Protein Persulfidation with Implications for Neurodegeneration as Exemplified by Friedreich's Ataxia.

Vo A, Khan U, Liopo A, Mouli K, Olson K, McHugh E Nanomaterials (Basel). 2024; 14(24.

PMID: 39728543 PMC: 11728766. DOI: 10.3390/nano14242007.

Differential Gene Expression in Late-Onset Friedreich Ataxia: A Comparative Transcriptomic Analysis Between Symptomatic and Asymptomatic Sisters.

Petrillo S, Perna A, Quatrana A, Silvestri G, Bertini E, Piemonte F Int J Mol Sci. 2024; 25(21).

PMID: 39519164 PMC: 11546378. DOI: 10.3390/ijms252111615.

CyaY and TusA regulate ISC- and SUF-mediated l-cysteine desulfurase activity.

Olivieri P, Crack J, Lehmann A, Le Brun N, Leimkuhler S RSC Chem Biol. 2024; .

PMID: 39372677 PMC: 11446229. DOI: 10.1039/d4cb00225c.

References

Shi R, Hou W, Wang Z, Xu X . Biogenesis of Iron-Sulfur Clusters and Their Role in DNA Metabolism. Front Cell Dev Biol. 2021; 9:735678. PMC: 8514734. DOI: 10.3389/fcell.2021.735678. View

Aratani Y . Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018; 640:47-52. DOI: 10.1016/j.abb.2018.01.004. View

Duby G, Foury F, Ramazzotti A, Herrmann J, Lutz T . A non-essential function for yeast frataxin in iron-sulfur cluster assembly. Hum Mol Genet. 2002; 11(21):2635-43. DOI: 10.1093/hmg/11.21.2635. View

Santucci R, Sinibaldi F, Cozza P, Polticelli F, Fiorucci L . Cytochrome c: An extreme multifunctional protein with a key role in cell fate. Int J Biol Macromol. 2019; 136:1237-1246. DOI: 10.1016/j.ijbiomac.2019.06.180. View

Pianese L, Tammaro A, Turano M, De Biase I, Monticelli A, Cocozza S . Identification of a novel transcript of X25, the human gene involved in Friedreich ataxia. Neurosci Lett. 2002; 320(3):137-40. DOI: 10.1016/s0304-3940(02)00048-4. View

Foury F, Pastore A, Trincal M . Acidic residues of yeast frataxin have an essential role in Fe-S cluster assembly. EMBO Rep. 2006; 8(2):194-9. PMC: 1796776. DOI: 10.1038/sj.embor.7400881. View

Adinolfi S, Iannuzzi C, Prischi F, Pastore C, Iametti S, Martin S . Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS. Nat Struct Mol Biol. 2009; 16(4):390-6. DOI: 10.1038/nsmb.1579. View

Wilson R, Roof D . Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat Genet. 1997; 16(4):352-7. DOI: 10.1038/ng0897-352. View

Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G . The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996; 59(3):554-60. PMC: 1914893. View

10.

Seguin A, Sutak R, Bulteau A, Garcia-Serres R, Oddou J, Lefevre S . Evidence that yeast frataxin is not an iron storage protein in vivo. Biochim Biophys Acta. 2010; 1802(6):531-8. DOI: 10.1016/j.bbadis.2010.03.008. View

11.

Tsou A, Paulsen E, Lagedrost S, Perlman S, Mathews K, Wilmot G . Mortality in Friedreich ataxia. J Neurol Sci. 2011; 307(1-2):46-9. DOI: 10.1016/j.jns.2011.05.023. View

12.

Fernandez-Frias I, Perez-Luz S, Diaz-Nido J . Analysis of Putative Epigenetic Regulatory Elements in the Genomic Locus. Int J Mol Sci. 2020; 21(10). PMC: 7279236. DOI: 10.3390/ijms21103410. View

13.

Cook A, Giunti P . Friedreich's ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017; 124(1):19-30. PMC: 5862303. DOI: 10.1093/bmb/ldx034. View

14.

Lazaropoulos M, Dong Y, Clark E, Greeley N, Seyer L, Brigatti K . Frataxin levels in peripheral tissue in Friedreich ataxia. Ann Clin Transl Neurol. 2015; 2(8):831-42. PMC: 4554444. DOI: 10.1002/acn3.225. View

15.

Hider R, Kong X . Iron speciation in the cytosol: an overview. Dalton Trans. 2012; 42(9):3220-9. DOI: 10.1039/c2dt32149a. View

16.

Leidgens S, De Smet S, Foury F . Frataxin interacts with Isu1 through a conserved tryptophan in its beta-sheet. Hum Mol Genet. 2009; 19(2):276-86. DOI: 10.1093/hmg/ddp495. View

17.

Martelli A, Wattenhofer-Donze M, Schmucker S, Bouvet S, Reutenauer L, Puccio H . Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum Mol Genet. 2007; 16(22):2651-8. DOI: 10.1093/hmg/ddm163. View

18.

Sen Gupta A . Hemoglobin-based Oxygen Carriers: Current State-of-the-art and Novel Molecules. Shock. 2019; 52(1S Suppl 1):70-83. PMC: 6874912. DOI: 10.1097/SHK.0000000000001009. View

19.

Martelli A, Puccio H . Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Front Pharmacol. 2014; 5:130. PMC: 4042101. DOI: 10.3389/fphar.2014.00130. View

20.

He Y, Alam S, Proteasa S, Zhang Y, Lesuisse E, Dancis A . Yeast frataxin solution structure, iron binding, and ferrochelatase interaction. Biochemistry. 2004; 43(51):16254-62. PMC: 2859087. DOI: 10.1021/bi0488193. View